The Effect of Assisted Reproductive Technology on Male Sexual Function.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04338087 |
Recruitment Status :
Completed
First Posted : April 8, 2020
Last Update Posted : April 8, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Erectile Dysfunction | Other: Questionnaire and personal interviews. |
Study Type : | Observational |
Actual Enrollment : | 734 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | The Correlation Between Assisted Reproductive Technology and Male Erectile Dysfunction. |
Actual Study Start Date : | January 1, 2017 |
Actual Primary Completion Date : | January 1, 2020 |
Actual Study Completion Date : | March 1, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
Fertility treatments
Men participating in fertility treatments.
|
Other: Questionnaire and personal interviews.
Questionnaire and personal interviews. |
Spontaneous pregnancy
Men whose wives conceived spontaneously.
|
Other: Questionnaire and personal interviews.
Questionnaire and personal interviews. |
- Changes in International index of erectile function score [ Time Frame: From recruitment up to 3 years. ]Changes in International index of erectile function score with a possible score ranging from 0 to 75. The higher the score, the better erectile function is.
- Sexual intercourse rate. [ Time Frame: From recruitment up to 3 years. ]Sexual intercourse rate as measured by the average monthly intercourse rate.
- Use of phospho-di-esterase 5 inhibitors [ Time Frame: From recruitment up to 3 years. ]Use of phospho-di-esterase 5 inhibitors as measured by the number of men using this medication.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Participation in fertility treatments.
Exclusion Criteria:
- None.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04338087
Israel | |
Rambam healthcare campus | |
Haifa, Israel |
Principal Investigator: | Roy Lauterbach, MD | Rambam healthcare campus |
Responsible Party: | ROY LAUTERBACH MD, Principal Investigator, Rambam Health Care Campus |
ClinicalTrials.gov Identifier: | NCT04338087 |
Other Study ID Numbers: |
0102-17-RMB |
First Posted: | April 8, 2020 Key Record Dates |
Last Update Posted: | April 8, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Erectile Dysfunction Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Mental Disorders |